Comments
Loading...

CRISPR Therapeutics Calificaciones de analistas

CRSPNASDAQ
Logotipo presentado por Benzinga Data
$67.74
-5.08-6.98%
al cierre: -
$68.00
0.260.38%
After hour: Oct 3, 7:48 PM EDT
Calificación de consenso1
Buy
Precio objetivo más alto1
$120.00
Precio objetivo más bajo1
$30.00
Precio objetivo consensuado1
$71.32

Calificaciones de analistas, precios objetivo, pronóstico

CRISPR Therapeutics AG ha un obiettivo di prezzo di consenso pari a $71.32, stabilito in base alle ultime valutazioni degli analisti di 28. Le ultime 3 valutazioni degli analisti sono state rilasciate da HC Wainwright & Co., JP Morgan y HC Wainwright & Co. il septiembre 23, 2025, septiembre 18, 2025 y agosto 7, 2025. Con un obiettivo di prezzo medio di $76.67 tra le HC Wainwright & Co., JP Morgan y HC Wainwright & Co., c'è un implicito 12.75% upside per CRISPR Therapeutics AG da queste valutazioni degli analisti.

Tendencia de los analistas
4
jun
2
jul
2
1
ago
2
sept
Compra
Mantener
Venta
Venta fuerte
Calificación de analistas
12345
3.1
Mantener
Compra fuerte
Compra
Mantener
Venta
Venta fuerte

Firmas de analistas que realizan recomendaciones1

HC Wainwright & Co.
JP Morgan
HC Wainwright & Co.
Barclays
Chardan Capital

1calculado a partir de las calificaciones de los analistas

Calificaciones de analistas para CRISPR Therapeutics

Buy Now
Get Alert
09/23/2025
17.65%
HC Wainwright & Co.
$80 → $80
Reiterates
Buy → Buy
09/18/2025
2.94%
JP Morgan
→ $70
Initiates
→ Overweight
08/07/2025
17.65%
HC Wainwright & Co.
$65 → $80
Maintains
Buy
08/06/2025
-17.65%
Barclays
$42 → $56
Maintains
Equal-Weight
08/05/2025
20.59%
Chardan Capital
$82 → $82
Maintains
Buy
08/05/2025
-38.24%
RBC Capital
$38 → $42
Maintains
Sector Perform
07/22/2025
14.71%
B of A Securities
$79 → $78
Maintains
Buy
07/08/2025
19.12%
Needham
$81 → $81
Reiterates
Buy → Buy
06/27/2025
-33.82%
Clear Street
→ $45
Downgrade
Buy → Hold
06/27/2025
54.41%
Piper Sandler
$105 → $105
Reiterates
Overweight → Overweight
06/27/2025
26.47%
JMP Securities
$86 → $86
Reiterates
Market Outperform → Market Outperform
06/27/2025
-4.41%
HC Wainwright & Co.
$65 → $65
Reiterates
Buy → Buy
06/26/2025
19.12%
Needham
$81 → $81
Reiterates
Buy → Buy
06/26/2025
20.59%
Chardan Capital
$82 → $82
Maintains
Buy
05/21/2025
26.47%
JMP Securities
$86 → $86
Reiterates
Market Outperform → Market Outperform
05/20/2025
19.12%
Needham
$81 → $81
Reiterates
Buy → Buy
05/20/2025
-4.41%
HC Wainwright & Co.
$65 → $65
Reiterates
Buy → Buy
05/09/2025
-38.24%
Barclays
$56 → $42
Maintains
Equal-Weight
05/08/2025
-30.88%
Goldman Sachs
$53 → $47
Maintains
Neutral
05/07/2025
19.12%
Needham
$84 → $81
Maintains
Buy
05/07/2025
20.59%
Chardan Capital
$84 → $82
Maintains
Buy
04/09/2025
23.53%
Needham
$84 → $84
Reiterates
Buy → Buy
02/19/2025
Cantor Fitzgerald
Reiterates
Neutral → Neutral
02/18/2025
20.59%
Citigroup
$89 → $82
Maintains
Buy
02/14/2025
-52.94%
Morgan Stanley
$30 → $32
Maintains
Underweight
02/14/2025
45.59%
Evercore ISI Group
$60 → $99
Upgrade
In-Line → Outperform
02/13/2025
-16.18%
Goldman Sachs
$66 → $57
Maintains
Neutral
02/13/2025
26.47%
JMP Securities
$86 → $86
Reiterates
Market Outperform → Market Outperform
02/13/2025
-27.94%
Stifel
$53 → $49
Maintains
Hold
02/13/2025
-4.41%
HC Wainwright & Co.
$65 → $65
Reiterates
Buy → Buy
02/13/2025
23.53%
Chardan Capital
$94 → $84
Maintains
Buy
02/12/2025
76.47%
Truist Securities
$100 → $120
Maintains
Buy
02/12/2025
-29.41%
RBC Capital
$53 → $48
Maintains
Sector Perform
02/12/2025
23.53%
Needham
$84 → $84
Reiterates
Buy → Buy
02/12/2025
-17.65%
Barclays
$55 → $56
Maintains
Equal-Weight
02/03/2025
-4.41%
HC Wainwright & Co.
→ $65
Initiates
→ Buy
01/14/2025
23.53%
Needham
$84 → $84
Reiterates
Buy → Buy
01/07/2025
25%
B of A Securities
$98 → $85
Maintains
Buy
12/20/2024
26.47%
JMP Securities
$86 → $86
Reiterates
Market Outperform → Market Outperform
12/10/2024
38.24%
Chardan Capital
$94 → $94
Maintains
Buy
11/06/2024
-22.06%
RBC Capital
$53 → $53
Reiterates
Sector Perform → Sector Perform
11/06/2024
-19.12%
Barclays
$59 → $55
Maintains
Equal-Weight
11/06/2024
23.53%
Needham
$84 → $84
Reiterates
Buy → Buy
10/04/2024
-22.06%
RBC Capital
$60 → $53
Maintains
Sector Perform
08/12/2024
47.06%
Truist Securities
$120 → $100
Maintains
Buy
08/08/2024
Cantor Fitzgerald
Reiterates
→ Neutral
08/06/2024
-13.24%
Stifel
$60 → $59
Maintains
Hold
08/06/2024
-13.24%
Barclays
$67 → $59
Maintains
Equal-Weight
08/06/2024
-11.76%
RBC Capital
$66 → $60
Maintains
Sector Perform
08/06/2024
38.24%
Chardan Capital
$112 → $94
Maintains
Buy
08/06/2024
23.53%
Needham
$88 → $84
Maintains
Buy
06/28/2024
Guggenheim
Assumes
→ Neutral
06/27/2024
29.41%
Needham
$88 → $88
Reiterates
Buy → Buy
06/17/2024
54.41%
Piper Sandler
$105 → $105
Reiterates
Overweight → Overweight
06/17/2024
29.41%
Needham
$88 → $88
Reiterates
Buy → Buy
05/23/2024
23.53%
Citigroup
$89 → $84
Maintains
Buy
05/10/2024
39.71%
Oppenheimer
$102 → $95
Maintains
Outperform
05/09/2024
26.47%
JMP Securities
$86 → $86
Reiterates
Market Outperform → Market Outperform
05/09/2024
-4.41%
Wells Fargo
$70 → $65
Maintains
Equal-Weight
05/09/2024
Cantor Fitzgerald
Reiterates
→ Neutral
05/09/2024
-1.47%
Barclays
$80 → $67
Maintains
Equal-Weight
05/09/2024
29.41%
Needham
$90 → $88
Maintains
Buy
05/09/2024
-23.53%
Baird
$46 → $52
Maintains
Neutral
04/18/2024
30.88%
Citigroup
$88 → $89
Maintains
Buy
04/11/2024
32.35%
Needham
$90 → $90
Reiterates
Buy → Buy
03/06/2024
45.59%
Mizuho
$82 → $99
Maintains
Buy
02/26/2024
-29.41%
Morgan Stanley
$46 → $48
Maintains
Underweight
02/22/2024
-2.94%
RBC Capital
$57 → $66
Maintains
Sector Perform
02/22/2024
2.94%
Wells Fargo
$55 → $70
Maintains
Equal-Weight
02/22/2024
17.65%
Barclays
$61 → $80
Maintains
Equal-Weight
02/22/2024
64.71%
Chardan Capital
$110 → $112
Maintains
Buy
02/21/2024
32.35%
Needham
$88 → $90
Maintains
Buy
02/15/2024
Wolfe Research
Initiates
→ Peer Perform
12/11/2023
-16.18%
RBC Capital
$50 → $57
Maintains
Sector Perform
12/11/2023
135.29%
Truist Securities
$220 → $160
Maintains
Buy
12/11/2023
-10.29%
Barclays
$56 → $61
Maintains
Equal-Weight
12/11/2023
-55.88%
TD Cowen
→ $30
Downgrade
Market Perform → Underperform
12/11/2023
17.65%
JMP Securities
$74 → $80
Maintains
Market Outperform
12/11/2023
29.41%
Needham
$85 → $88
Maintains
Buy
12/08/2023
223.53%
Truist Securities
→ $220
Reiterates
Buy → Buy
12/08/2023
20.59%
Mizuho
→ $82
Reiterates
Buy → Buy
12/05/2023
8.82%
JMP Securities
→ $74
Reiterates
Market Outperform → Market Outperform
11/13/2023
-38.24%
Morgan Stanley
$43 → $42
Maintains
Underweight
11/07/2023
-26.47%
RBC Capital
$55 → $50
Maintains
Sector Perform
11/07/2023
25%
Needham
$88 → $85
Maintains
Buy
11/01/2023
29.41%
Needham
→ $88
Reiterates
Buy → Buy
10/30/2023
29.41%
Needham
→ $88
Reiterates
Buy → Buy
10/17/2023
Cantor Fitzgerald
Downgrade
Overweight → Neutral
09/27/2023
20.59%
Mizuho
→ $82
Initiates
→ Buy
08/18/2023
2.94%
Citigroup
→ $70
Upgrade
Neutral → Buy
08/17/2023
2.94%
Citigroup
→ $70
Upgrade
Neutral → Buy
08/14/2023
-36.76%
Morgan Stanley
$42 → $43
Maintains
Underweight
08/10/2023
50%
Oppenheimer
→ $102
Reiterates
Outperform → Outperform
08/08/2023
-7.35%
Credit Suisse
$62 → $63
Maintains
Neutral
08/08/2023
10.29%
EF Hutton
→ $75
Reiterates
Buy → Buy
08/08/2023
29.41%
Needham
→ $88
Reiterates
Buy → Buy
08/08/2023
61.76%
Chardan Capital
$123 → $110
Maintains
Buy
07/25/2023
8.82%
JMP Securities
→ $74
Reiterates
Market Outperform → Market Outperform
06/09/2023
29.41%
Needham
$82 → $88
Reiterates
Buy → Buy
06/09/2023
8.82%
JMP Securities
$70 → $74
Maintains
Market Outperform

PREGUNTAS FRECUENTES

Q

¿Cuál es el precio objetivo de las acciones de CRISPR Therapeutics (CRSP)?

A

El último precio objetivo de CRISPR Therapeutics (NASDAQ:CRSP) fue comunicado por HC Wainwright & Co. el septiembre 23, 2025. La firma de analistas fijó un precio objetivo para $80.00 que espera CRSP a rise dentro de 12 meses (un posible 17.65% upside). 43 firmas de analistas han reportado calificaciones en el último año.

Q

¿Cuál es la calificación más reciente de los analistas sobre CRISPR Therapeutics (CRSP)?

A

La última calificación de analistas para CRISPR Therapeutics (NASDAQ:CRSP) fue proporcionada por HC Wainwright & Co., y CRISPR Therapeutics reiterado su buy calificación.

Q

¿Cuándo se produjo la última revisión al alza de CRISPR Therapeutics (CRSP)?

A

La última revisión al alza de CRISPR Therapeutics AG se produjo en febrero 14, 2025, cuando Evercore ISI Group elevó su precio objetivo a $99. Evercore ISI Group anteriormente tenía an in-line para CRISPR Therapeutics AG.

Q

¿Cuándo fue la última revisión a la baja de CRISPR Therapeutics (CRSP)?

A

La última revisión a la baja de CRISPR Therapeutics AG se produjo en junio 27, 2025, cuando Clear Street cambió su precio objetivo de N/A a $45 para CRISPR Therapeutics AG.

Q

¿Cuándo se publicará o actualizará la próxima calificación de los analistas para CRISPR Therapeutics (CRSP)?

A

Los analistas llegan a las calificaciones de acciones después de hacer una investigación exhaustiva, que incluye revisar los estados financieros públicos, hablar con ejecutivos y clientes de CRISPR Therapeutics, y escuchar las teleconferencias de ganancias. La mayoría de los analistas hacen esto cada tres meses, por lo que deberías recibir 4 calificaciones por empresa al año. La última calificación de CRISPR Therapeutics se registró el septiembre 23, 2025, por lo que la próxima calificación estará disponible en torno al septiembre 23, 2026.

Q

¿Es correcta la calificación de los analistas sobre CRISPR Therapeutics (CRSP)?

A

Aunque las calificaciones son subjetivas y pueden cambiar, la última calificación de CRISPR Therapeutics (CRSP) fue un reiterado con un precio objetivo de $80.00 a $80.00. El precio actual al que cotiza CRISPR Therapeutics (CRSP) es de $68.00, que es out of del rango previsto por el analista.

Explora calificaciones de analistas y precios objetivo sobre todos los valores.

La gente también mira